U.S. Stock Market Midday Update
NewcelX fell 16.10%, with increased trading volume. Based on recent key news:
<ol>
<li>
On April 30, NewcelX announced a net loss of $8.3 million for 2025, of which $5.7 million was a non-cash expense related to the revaluation of derivative liabilities. The company expects to focus on advancing key milestones for NCEL-101 in 2026, expanding collaborations, and accelerating development. This news raised investor concerns about the company's future development, leading to a significant drop in stock price.
</li>
<li>
On April 30, NewcelX partnered with Eledon Pharmaceuticals to develop a treatment for Type 1 diabetes, combining stem cell-derived islet replacement and immune modulation technologies. Despite the promising collaboration prospects, analysts reassessed the company's expectations and valuations in the current challenging biotechnology financing environment, leading to a negative shift in market sentiment.
</li>
<li>
On April 30, NewcelX announced a high-priced private placement and equity raise aimed at extending the funding timeline for NCEL-101 and a broader pipeline. However, this financing move failed to alleviate market concerns about the company's financial situation, further exacerbating the stock price decline. The biotechnology financing environment remains tough, and market sentiment is cautious.
</li>
</ol>
Top Stocks by Trading Volume in the Industry
Amgen fell 4.89%. Based on recent key news:
<ol>
<li>
On May 1, Amgen reported first-quarter earnings that exceeded expectations, raising its full-year revenue forecast to between $37.1 billion and $38.5 billion, which drove stock price volatility. Source: Zhitong Finance
</li>
<li>
On May 1, the U.S. FDA proposed to withdraw approval for Amgen's drug Tavneos due to doubts about its efficacy and serious safety issues, including liver damage and death cases, increasing regulatory risks. Source: Wall Street Insight
</li>
<li>
On May 1, analyst rating changes saw Bank of America maintain a sell rating with a target price of $307, as the market remains cautious about Amgen's future performance. Source: Jinshi Data, with increasing competition in the pharmaceutical industry and rising regulatory risks.
</li>
</ol>
Cue BioPharma rose 97.52%. Based on recent key news:
<ol>
<li>
On April 30, Cue Biopharma announced a $30 million private financing round aimed at advancing the company's clinical pipeline, including the acquisition and development of Ascendant-221, which significantly boosted the stock price. Source: Company announcement
</li>
<li>
On May 1, Cue Biopharma signed an exclusive licensing agreement with Ascendant Health Sciences to develop, manufacture, and commercialize Ascendant-221. This news further boosted market confidence, driving the stock price up. Source: Company announcement
</li>
<li>
On May 1, Cue Biopharma appointed Shao-Lee Lin as the new CEO, with the market having high expectations for his leadership, further driving the stock price increase
Source: Company Announcement The biopharmaceutical industry has recently shown active performance, with significant capital inflow.
</li>
</ol>
AbbVie fell 0.40%, with increased trading volume. Based on recent key news:
<ol>
<li>
On April 29, AbbVie reported first-quarter results that exceeded expectations, with adjusted earnings per share of $2.65, higher than the market expectation of $2.59, and revenue reaching $15 billion, surpassing the expected $14.7 billion. This news drove the stock price up.
</li>
<li>
On April 29, AbbVie raised its full-year profit forecast, expecting adjusted earnings per share of $14.08 to $14.28 in 2026, an upward adjustment from previous guidance. This move boosted market confidence, benefiting the stock price.
</li>
<li>
On April 29, AbbVie's immunology drugs Skyrizi and Rinvoq showed strong sales performance, increasing by 31% and 23% respectively, offsetting the decline in Humira sales, further supporting the rise in stock price. Strong demand for immunology drugs supports the stock price.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Gilead Sciences fell 0.07%. Based on recent key news:
<ol>
<li>
On April 28, Gilead Sciences completed the acquisition of Arcellx, which is expected to drive the commercialization of Anito-cel. This move may enhance the company's competitiveness in the cell therapy field, positively impacting the stock price;
</li>
<li>
On April 28, Gilead Sciences Chairman and CEO Daniel Patrick O’Day sold 10,000 shares of common stock, leading to market doubts about internal confidence in the company, causing slight fluctuations in the stock price;
</li>
<li>
On May 1, analyst ratings indicated Gilead Sciences as &#34;moderate buy,&#34; but five other stocks were considered more valuable investments, affecting market confidence in Gilead. The biopharmaceutical industry has recently performed strongly, with a focus on innovative drugs
</li>
</ol>

NCEL

NewcelX fell 16.10%; Amgen fell 4.89%, with a trading volume of USD 375 million; Cue BioPharma rose 97.52%, with a trading volume of USD 375 million; AbbVie fell 0.40%, with a trading volume of USD 324 million; Gilead Sciences fell 0.07%, with a market capitalization of USD 162.3 billion

Price Alert

NewcelX

U.S. stock market update: NewcelX down 16.10%, financial losses and worsening financing environment raise market concerns